Novo Nordisk stated that replacing Jørgensen is “in the best interests of the company and its shareholders”.

The EC has approved BMS’ perioperative regimen of neoadjuvant Opdivo combined with chemotherapy for NSCLC.

Research has shown a gap between the female patient experience compared to those of men.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why seamless communication and treatment continuity across primary care, cardiology, and rehabilitation are critical to improving outcomes and preventing care gaps for cardiovascular […]

Global regulators continue to raise the bar on sterile drug manufacturing—and West is responding.

Timely, high-integrity insights for sponsors that reduce risk and move trials forward.

Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.

BioMarin Pharmaceutical has signed a definitive agreement to acquire Inozyme Pharma in an all-cash transaction valued at $270m.

Imagene is the Innovation award winner in the Precision Oncology category in the 2025 Pharmaceutical Excellence Awards.

Explore Novotech CEO John Moller’s insights on the company’s global expansion, commitment to diversity, and innovative approaches in clinical research. Discover how Novotech is shaping the future of clinical trials with a focus on inclusivity and […]

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.

View the Pharmaceutical Executive May 2025 issue in an interactive format.

Tapping into the reader experience, our new comprehensive survey uncovers valuable input for navigating the changing tides facing pharma decision-makers.

Our exclusive poll captures today’s top trends and perspectives—shaped by those pharma decision-makers impacted the most.

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” market opportunity for Inozyme’s main drug.

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was terminated in April.

Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act.

US President Donald Trump has resurrected a drug pricing plan that equates to International Reference Pricing.